Lilly's Evista Osteoporosis Treatment Label Cites 55% Risk Reduction
Executive Summary
Lilly's Evista enters the osteoporosis treatment market with a labeled 55% risk reduction for first vertebral fracture following supplemental approval for the treatment of osteoporosis in postmenopausal women Sept. 30.